Citigroup’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63.2M Buy
789,574
+169,775
+27% +$14M 0.03% 556
2025
Q4
$52.8M Sell
619,799
-252,268
-29% -$20.7M 0.02% 617
2025
Q3
$67.8M Sell
872,067
-513,348
-37% -$40.1M 0.03% 512
2025
Q2
$108M Buy
1,385,415
+361,986
+35% +$27M 0.05% 325
2025
Q1
$74.2M Buy
1,023,429
+182,238
+22% +$13M 0.04% 415
2024
Q4
$62.3M Sell
841,191
-154,689
-16% -$10.8M 0.04% 435
2024
Q3
$65.7M Buy
995,880
+511,530
+106% +$37.2M 0.04% 407
2024
Q2
$44.7M Buy
484,350
+133,945
+38% +$11.9M 0.03% 533
2024
Q1
$33.5M Sell
350,405
-23,853
-6% -$2M 0.02% 656
2023
Q4
$28.5M Sell
374,258
-51,283
-12% -$3.57M 0.02% 689
2023
Q3
$29.5M Sell
425,541
-70,288
-14% -$5.65M 0.02% 611
2023
Q2
$46.8M Sell
495,829
-29,362
-6% -$2.55M 0.03% 458
2023
Q1
$43.4M Buy
525,191
+92,745
+21% +$7.29M 0.03% 457
2022
Q4
$32.3M Sell
432,446
-18,566
-4% -$1.43M 0.03% 571
2022
Q3
$37.3M Buy
451,012
+82,945
+23% +$7.98M 0.03% 484
2022
Q2
$35M Buy
368,067
+41,990
+13% +$4.35M 0.03% 532
2022
Q1
$38.4M Sell
326,077
-32,112
-9% -$3.6M 0.02% 604
2021
Q4
$46.4M Sell
358,189
-13,677
-4% -$1.6M 0.02% 591
2021
Q3
$42.1M Sell
371,866
-434,476
-54% -$49.6M 0.02% 612
2021
Q2
$83.5M Buy
806,342
+242,022
+43% +$22.8M 0.05% 353
2021
Q1
$47.2M Sell
564,320
-10,162
-2% -$859K 0.03% 515
2020
Q4
$52.4M Buy
574,482
+100,892
+21% +$8.37M 0.03% 517
2020
Q3
$37.8M Sell
473,590
-20,227
-4% -$1.58M 0.02% 582
2020
Q2
$34.1M Buy
493,817
+204,998
+71% +$14.6M 0.03% 549
2020
Q1
$18.2M Sell
288,819
-18,432
-6% -$1.33M 0.02% 794
2019
Q4
$23.9M Sell
307,251
-50,313
-14% -$3.93M 0.02% 865
2019
Q3
$26.2M Sell
357,564
-79,107
-18% -$5.56M 0.02% 773
2019
Q2
$26.9M Buy
436,671
+149,739
+52% +$9.05M 0.02% 763
2019
Q1
$18.3M Buy
286,932
+138,957
+94% +$7.93M 0.02% 885
2018
Q4
$7.55M Sell
147,975
-403,245
-73% -$20.4M 0.01% 1477
2018
Q3
$32M Buy
551,220
+414,672
+304% +$20.3M 0.03% 584
2018
Q2
$6.63M Sell
136,548
-55,389
-29% -$2.59M 0.01% 1592
2018
Q1
$8.93M Buy
191,937
+85,767
+81% +$3.72M 0.01% 1321
2017
Q4
$3.99M Sell
106,170
-118,398
-53% -$4.35M ﹤0.01% 2055
2017
Q3
$8.18M Buy
224,568
+98,796
+79% +$3.77M 0.01% 1372
2017
Q2
$4.96M Sell
125,772
-183,468
-59% -$6.7M ﹤0.01% 1694
2017
Q1
$9.7M Buy
309,240
+273,102
+756% +$8.55M 0.01% 1153
2016
Q4
$1.13M Sell
36,138
-158,445
-81% -$5.13M ﹤0.01% 3552
2016
Q3
$7.82M Buy
194,583
+182,682
+1,535% +$6.88M 0.01% 1272
2016
Q2
$396K Sell
11,901
-40,188
-77% -$1.37M ﹤0.01% 3886
2016
Q1
$1.53M Sell
52,089
-39,195
-43% -$1.08M ﹤0.01% 2827
2015
Q4
$2.4M Buy
91,284
+67,626
+286% +$1.76M ﹤0.01% 2344
2015
Q3
$561K Sell
23,658
-310,230
-93% -$7.49M ﹤0.01% 3637
2015
Q2
$7.93M Buy
333,888
+82,740
+33% +$1.87M 0.01% 1378
2015
Q1
$5.96M Buy
251,148
+81,798
+48% +$1.84M 0.01% 1592
2014
Q4
$3.6M Buy
169,350
+70,104
+71% +$1.41M ﹤0.01% 2038
2014
Q3
$1.69M Sell
99,246
-57,144
-37% -$902K ﹤0.01% 2667
2014
Q2
$2.24M Sell
156,390
-11,682
-7% -$158K ﹤0.01% 2401
2014
Q1
$2.08M Sell
168,072
-513,192
-75% -$5.92M ﹤0.01% 2332
2013
Q4
$7.47M Buy
681,264
+360,036
+112% +$4.06M 0.01% 1472
2013
Q3
$3.73M Sell
321,228
-263,976
-45% -$3.09M ﹤0.01% 2007
2013
Q2
$6.55M Buy
+585,204
New +$6.93M 0.01% 1399

Other funds holding EW

Citigroup's EW Position: Q1 2026 in Review

Citigroup increased its Edwards Lifesciences (EW) stake by 27% in Q1 2026, buying an estimated $14M and bringing the position to 789,574 shares worth $63.2M. The position accounts for 0.03% of the portfolio, ranked #556.

Citigroup first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $108M in Q2 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Citigroup held 789,574 shares of Edwards Lifesciences worth $63.2M as of Q1 2026.
  • Citigroup bought 169,775 Edwards Lifesciences shares in Q1 2026, an estimated $14M.
  • Edwards Lifesciences made up 0.03% of Citigroup's portfolio in Q1 2026, its #556 holding.
  • Citigroup first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Edwards Lifesciences position peaked at $108M in Q2 2025.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.